Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SIDNEY E CLEVINGER

Allopathic & Osteopathic Physicians Family Medicine

NPI
1760461974
CMS profile
351917
Location
OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$53.55

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $53.55 3

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $21.46 1
GlaxoSmithKline, LLC. $17.21 1
SANOFI PASTEUR INC. $14.88 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SIDNEY E CLEVINGER

NPI 1760461974 · CMS profile ID 351917

Allopathic & Osteopathic Physicians / Family Medicine

OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760461974?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SIDNEY E CLEVINGER, NPI 1760461974, CMS profile ID 351917. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760461974?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). SIDNEY E CLEVINGER, NPI 1760461974, CMS profile ID 351917. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760461974?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
SIDNEY E CLEVINGER, NPI 1760461974, CMS profile ID 351917, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1760461974?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $53.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $21.4602/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736002227 CMS
GlaxoSmithKline, LLC. $17.2102/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738477597 CMS
SANOFI PASTEUR INC. $14.8802/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744027331 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $110,053.76 24
PY2020 $53.55 3
PY2021 $20.97 1
PY2022 $27.81 1
PY2023 $103.79 1
PY2024 $57.75 3
PY2025 $14.33 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $3,000.00 1
PY2022 Principal investigator $11,160.95 10
PY2021 Principal investigator $6,708.88 3
PY2020 Principal investigator $51,931.83 11
PY2019 Recipient $4,464.00 1
PY2019 Principal investigator $92,285.11 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,872.03 12/05/2019 Non-covered Recipient Entity
RENSTAR INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685014195
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,000.00 11/28/2019 Non-covered Recipient Entity
RENSTAR INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685014183
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 11/28/2019 Non-covered Recipient Entity
RENSTAR INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685014187
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $71.82 11/28/2019 Non-covered Recipient Entity
RENSTAR INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685014191
Principal investigator 1 Eisai Inc. $460.40 08/22/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702537611
Principal investigator 1 Eisai Inc. $4,094.30 08/22/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702537613
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15.00 05/22/2019 Non-covered Recipient Individual A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027406
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $18.60 05/22/2019 Non-covered Recipient Individual A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027413
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27.00 05/22/2019 Non-covered Recipient Individual A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027423
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $42.92 05/22/2019 Non-covered Recipient Individual A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027431
Principal investigator 1 Eisai Inc. $1,000.00 04/04/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538157
Principal investigator 1 Eisai Inc. $2,350.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538105
Principal investigator 1 Eisai Inc. $2,350.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538107
Principal investigator 1 Eisai Inc. $2,350.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538109
Principal investigator 1 Eisai Inc. $839.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538111
Principal investigator 1 Eisai Inc. $1,699.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538113
Principal investigator 1 Eisai Inc. $1,567.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538115
Principal investigator 1 Eisai Inc. $911.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538117
Principal investigator 1 Eisai Inc. $1,567.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538119
Principal investigator 1 Eisai Inc. $337.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538121
Principal investigator 1 Eisai Inc. $1,515.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538123
Principal investigator 1 Eisai Inc. $839.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538125
Principal investigator 1 Eisai Inc. $2,350.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538127
Principal investigator 1 Eisai Inc. $1,699.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538129
Principal investigator 1 Eisai Inc. $1,567.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538131
Principal investigator 1 Eisai Inc. $911.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538133
Principal investigator 1 Eisai Inc. $1,567.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538135
Principal investigator 1 Eisai Inc. $337.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538137
Principal investigator 1 Eisai Inc. $2,350.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538139
Principal investigator 1 Eisai Inc. $337.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538141
Principal investigator 1 Eisai Inc. $1,567.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538143
Principal investigator 1 Eisai Inc. $337.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538145
Principal investigator 1 Eisai Inc. $337.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538147
Principal investigator 1 Eisai Inc. $1,567.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538149
Principal investigator 1 Eisai Inc. $337.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538151
Principal investigator 1 Eisai Inc. $2,350.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538153
Principal investigator 1 Eisai Inc. $2,350.00 04/02/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702538155
Principal investigator 1 Eisai Inc. $1,050.00 03/05/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702537475
Principal investigator 1 Eisai Inc. $1,000.00 03/05/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702537477
Principal investigator 1 Eisai Inc. $1,500.00 03/05/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702537479
Principal investigator 1 Merck Sharp & Dohme Corporation $2,237.40 02/26/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU - DAY. No dispute reported 06/30/2026 691320611
Principal investigator 1 Eisai Inc. $1,467.00 02/19/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702537451
Principal investigator 1 Eisai Inc. $1,519.00 02/19/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702537453
Principal investigator 1 Eisai Inc. $1,661.00 02/19/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702537455
Principal investigator 1 Eisai Inc. $1,376.00 02/19/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702537457
Principal investigator 1 Eisai Inc. $337.00 01/31/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702537463
Principal investigator 1 Eisai Inc. $1,709.00 01/31/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702537465
Principal investigator 1 Eisai Inc. $1,424.00 01/31/2019 Non-covered Recipient Entity
RENSTAR INC
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702537467
Principal investigator 1 Eli Lilly and Company $12,756.00 01/28/2019 Non-covered Recipient Entity
RENSTAR INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY No dispute reported 06/30/2026 654293355
Principal investigator 1 Merck Sharp & Dohme Corporation $4,474.80 01/22/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU - DAY. No dispute reported 06/30/2026 691309461
Recipient Eli Lilly and Company $4,464.00 01/18/2019 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY No dispute reported 06/30/2026 654284159
Principal investigator 1 Merck Sharp & Dohme Corporation $300.00 01/03/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU - DAY. No dispute reported 06/30/2026 691310979
Principal investigator 1 Merck Sharp & Dohme Corporation $84.84 01/02/2019 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU - DAY. No dispute reported 06/30/2026 691291083